MediWound Ltd. (MDWD)

About MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 77 institutions reported holding MDWD, with 5.8 million shares worth $85.5 million in aggregate. The largest reported holder was Investor AB, with 872,093 shares worth $12.8 million. Of the 5 largest holders listed below, 1 added shares, 2 reduced their positions and 2 held their positions unchanged during the quarter.

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions